ORYZON announces First Patient in the US in ETHERAL-US: a Phase IIa clinical trial with vafidemstat in Alzheimer’s Disease
MADRID, SPAIN and CAMBRIDGE MA.
• ETHERAL Europe reached 100 patients randomized last week
Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in the US in its Phase IIa clinical trial with vafidemstat in Alzheimer’s disease (AD). The study, named ETHERAL-US (Epigenetic THERapy in ALzheimer’s Disease), is being conducted in the United States (US).